U.S., May 31 -- ClinicalTrials.gov registry received information related to the study (NCT06997484) titled 'First-in-Human Single and Multiple Dose of HL-400' on May 13.
Brief Summary: This is a randomized, double-blind, placebo-controlled, dose-escalation study in healthy subjects to evaluate the safety, tolerability, pharmacokinetics of HL-400 (a NLRP3 inhibitor) following oral single and multiple ascending dose administration.
Study Start Date: April 25
Study Type: INTERVENTIONAL
Condition:
Parkinson Disease
Intervention:
DRUG: HL-400
Part 1:Experimental: Single oral dose of HL-400, Single ascending doses, sequential assignment group design; Part 2: Experimental: Multiple oral doses of HL-400, Multiple ascending doses, QD for 14 ...